Allena Pharmaceuticals, Inc. (ALNA)
Stock Price:
$1.54 USD
-0.05 (-3.14%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
49.37M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-43.51M |
| Shares Out |
24.88M |
| EPS (ttm) |
-1.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$1.54 |
| Previous Close |
$1.59 |
| Change ($) |
-0.05 |
| Change (%) |
-3.14% |
| Day's Open |
1.60 |
| Day's Range |
1.51 - 1.61 |
| Day's Volume |
440,195 |
| 52-Week Range |
0.53 - 6.30 |
More Stats
| Market Cap |
49.37M |
| Enterprise Value |
38.33M |
| Earnings Date (est) |
Aug 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
24.88M |
| Float |
9.23M |
| EPS (basic) |
-1.89 |
| EPS (diluted) |
-1.88 |
| FCF / Share |
-1.72 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
435,043 |
| Short Ratio |
0.36 |
| Short % of Float |
1.72% |
| Beta |
2.91 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.14 |
| Revenue |
n/a |
| Operating Income |
-43.49M |
| Net Income |
-43.51M |
| Free Cash Flow |
-42.42M |
| Net Cash |
11.04M |
| Net Cash / Share |
0.34 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-68.30% |
| ROE |
-176.36% |
| ROIC |
-882.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
6 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$9.00*
(484.42% upside)
Low
1.00
Current: 1.54
High
26.00
Target: 9.00
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -47.53 | -35.59 | -20.95 | -24.19 | -13.91 |
| Net Income | -47.34 | -35.65 | -21.65 | -24.51 | -14.25 |
| Shares Outstanding | 22.18 | 20.74 | 4.52 | 1.34 | 1.26 |
| Earnings Per Share | -2.13 | -1.72 | -4.80 | -18.35 | -11.35 |
| Operating Cash Flow | -43.63 | -31.84 | -21.07 | -23.39 | -13.18 |
| Capital Expenditures | -0.12 | -0.32 | -0.06 | -0.10 | 0.01 |
| Free Cash Flow | -43.75 | -32.16 | -21.12 | -23.50 | -13.17 |
| Cash & Equivalents | 30.01 | 61.64 | 94.49 | 48.76 | 69.01 |
| Total Debt | 10.49 | 9.98 | 9.39 | 9.59 | 6.19 |
| Net Cash / Debt | 19.52 | 51.66 | 85.11 | 39.17 | 62.83 |
| Assets | 34.11 | 65.23 | 96.25 | 49.48 | 70.01 |
| Liabilities | 16.91 | 15.77 | 13.38 | 13.03 | 9.32 |
| Book Value | 17.20 | 49.46 | 82.87 | -59.28 | -34.97 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Allena Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
33 |
| CEO |
Louis Brenner |
Stock Information
| Ticker Symbol |
ALNA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ALNA |
| IPO Date |
November 2, 2017 |
Description
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.